Product Description
an investigational therapy for sickle cell disease (SCD) (Sourced from: https://ashpublications.org/ashclinicalnews/news/2915/Vepoloxamer-Does-Not-Meet-Primary-Endpoint-in)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Savara
Company Location: AUSTIN TX 78746
Company CEO: Matthew Pauls
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Anemia, Sickle Cell
Phase 2: Other|Heart Failure, Chronic
Phase 1: Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Evaluation of Purified Poloxamer 188 in Subjects in Crisis (EPIC) | P3 |
Completed |
Anemia, Sickle Cell |
2017-01-16 |
|
| MST-188-07 | P2 |
Terminated |
Other |
2016-12-01 |
|
| MST-188-10 | P1 |
Completed |
Kidney Diseases |
2016-11-01 |
|
| MST-188-09 | P2 |
Terminated |
Heart Failure, Chronic |
2016-10-01 |